These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21287303)

  • 1. Livedo reticularis and related disorders.
    Dean SM
    Curr Treat Options Cardiovasc Med; 2011 Apr; 13(2):179-91. PubMed ID: 21287303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review.
    Kraemer M; Linden D; Berlit P
    J Neurol; 2005 Oct; 252(10):1155-66. PubMed ID: 16133722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Livedo Racemosa: Clinical, Laboratory, and Histopathological Findings in 33 Patients.
    Pincelli MS; Echavarria AMJ; Criado PR; Marques GF; Morita TCAB; Valente NYS; de Carvalho JF
    Int J Low Extrem Wounds; 2021 Mar; 20(1):22-28. PubMed ID: 31996060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in anti-phosphatidylserine-prothrombin complex antibodies and cutaneous vasculitis between regular livedo reticularis and livedo racemosa.
    Kawakami T; Yamazaki M; Mizoguchi M; Soma Y
    Rheumatology (Oxford); 2009 May; 48(5):508-12. PubMed ID: 19273539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Livedo reticularis, cerebrovascular disorders and mitral disease: a new cause of Sneddon's syndrome?].
    Vaillant L; Larmande P; Arbeille B; Desveaux B; Gruel Y; Lorette G
    Ann Dermatol Venereol; 1990; 117(12):925-30. PubMed ID: 2082786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amantadine-Induced Livedo Racemosa.
    Criado PR; Alavi A; Valente NY; Sotto MN
    Int J Low Extrem Wounds; 2016 Mar; 15(1):78-81. PubMed ID: 26338517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination of livedo racemosa, occlusion of cerebral blood vessels, and nephropathy: kidney involvement in Sneddon's syndrome.
    Ohtani H; Imai H; Yasuda T; Wakui H; Komatsuda A; Hamai K; Miura AB
    Am J Kidney Dis; 1995 Sep; 26(3):511-5. PubMed ID: 7645561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients.
    Francès C; Papo T; Wechsler B; Laporte JL; Biousse V; Piette JC
    Medicine (Baltimore); 1999 Jul; 78(4):209-19. PubMed ID: 10424203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Livedo racemosa in neurological diseases: an update on the differential diagnoses.
    Mitri F; Enk A; Bersano A; Kraemer M
    Eur J Neurol; 2020 Oct; 27(10):1832-1843. PubMed ID: 32526049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Livedo racemosa as a marker of increased risk of recurrent thrombosis in patients with negative anti-phospholipid antibodies.
    Martínez-Valle F; Ordi-Ros J; Selva-O'Callaghan A; Balada E; Solans-Laque R; Vilardell-Tarres M
    Med Clin (Barc); 2009 May; 132(20):767-71. PubMed ID: 19403146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sneddon's syndrome (livedo reticularis and cerebral thrombosis) with livedo vasculitis and anticardiolipin antibodies.
    Grattan CE; Burton JL; Boon AP
    Br J Dermatol; 1989 Mar; 120(3):441-7. PubMed ID: 2636849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Livedo reticularis: A review of the literature.
    Sajjan VV; Lunge S; Swamy MB; Pandit AM
    Indian Dermatol Online J; 2015; 6(5):315-21. PubMed ID: 26500860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-beta 2 glycoprotein 1 antibodies in idiopathic livedo reticularis].
    Aubry F; Crickx B; Nicaise P; Labarre C; Viard JP; Belaïch S
    Ann Dermatol Venereol; 1995; 122(10):667-70. PubMed ID: 8687049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Livedo reticularis following administration of ChAdOx1 nCoV-19 vaccine (AZD1222): a report of two cases.
    Kim JH; Uh JA; Kim HS; Lee SK; Kim MS; Lee UH
    Clin Exp Vaccine Res; 2022 Sep; 11(3):298-301. PubMed ID: 36451671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and immunologic features of livedo reticularis in lupus: a case-control study.
    Englert HJ; Loizou S; Derue GG; Walport MJ; Hughes GR
    Am J Med; 1989 Oct; 87(4):408-10. PubMed ID: 2801732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Livedo reticularis and cerebrovascular accidents (Sneddon's syndrome) as a clinical expression of antiphospholipid syndrome.
    Gantcheva M; Tsankov N
    J Eur Acad Dermatol Venereol; 1999 Mar; 12(2):157-60. PubMed ID: 10343946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous manifestations of antiphospholipid antibody syndrome.
    Weinstein S; Piette W
    Hematol Oncol Clin North Am; 2008 Feb; 22(1):67-77, vi. PubMed ID: 18207066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of antiphospholipid antibodies in a patient with Sneddon's syndrome and her family.
    Lousa M; Sastre JL; Cancelas JA; Gobernado JM; Pardo A
    Stroke; 1994 May; 25(5):1071-4. PubMed ID: 8165682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sneddon's syndrome: case report and review of its relationship with antiphospholipid syndrome.
    Dutra LA; Braga-Neto P; Pedroso JL; Barsottini OG
    Einstein (Sao Paulo); 2012; 10(2):230-2. PubMed ID: 23052460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cerebrovascular disorders associated with livedo (Sneddon's syndrome): its relation to lupus anticoagulant].
    Kalashnikova LA; Prudnikova LZ; Nasonov EP
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(7):104-7. PubMed ID: 2175072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.